Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Int. j. cardiovasc. sci. (Impr.) ; 33(4): 307-317, July-Aug. 2020. tab, graf
Article in English | LILACS | ID: biblio-1134380

ABSTRACT

Abstract Background: Patent foramen ovale (PFO) closure has been compared to medical therapy for secondary prevention of recurrent cryptogenic stroke. Objectives: To produce an updated meta-analysis including only data from the primary analyses of clinical trials and to evaluate the role of PFO closure in the secondary prevention of recurrent stroke. Methods: Search in Medline (PubMed) and in ISI Web of Knowledge. Parameters under analysis and meta-analyses were: stroke, transient ischemic attack (TIA) and atrial fibrillation (AF). Comprehensive Meta-analysis Software V.2.0 (Biostat) was used. Random-effects analyses were carried out. A level of significance of 5% was used. Results: In this study six, randomized trials enrolling 3,750 patients were included. Unlike other published meta-analyses on the same topic, in this case, only clinical trial data, and not follow-up data, were used. PFO closure, as compared with medical therapy alone, demonstrated superiority in reducing the rate of recurrent stroke (risk ratio with PFO closure vs. medical therapy, 0.37; 95% confidence interval [CI], 0.17 to 0.78; p = 0.01). PFO closure did not offer a significant benefit in prevention of TIA (risk ratio with PFO closure vs. medical therapy, 0.96; 95% CI, 0.64 to 1.44; p = 0.85). Among patients assigned to closure group, an increased risk of atrial fibrillation was seen (risk ratio with PFO closure vs. medical therapy, 4.64; 95% CI, 2.38 to 9.01; p < 0.01). Conclusions: In patients with cryptogenic stroke who had a patent foramen ovale, a protective effect of closure was seen concerning the risk of recurrent stroke, but not regarding the prevention of TIA.


Subject(s)
Stroke/prevention & control , Foramen Ovale, Patent/diagnosis , Secondary Prevention , Atrial Fibrillation , Ischemic Attack, Transient , Foramen Ovale, Patent/surgery , Heart Disease Risk Factors
2.
Shock ; 53(5): 616-619, 2020 05.
Article in English | MEDLINE | ID: mdl-31232863

ABSTRACT

Septic cardiomyopathy is an increasingly relevant topic in clinical management of septic shock. However, pathophysiological mechanisms and long-term consequences of sepsis-induced myocardial injury are still poorly understood. Herein, new clinical and histological evidence is provided suggesting an association of myocardial edema formation with tissue injury and subsequent remodeling in septic shock patients. This preliminary data supports myocardial edema as a potentially relevant and largely unexplored mechanism of human septic cardiomyopathy.


Subject(s)
Cardiomyopathies/etiology , Edema/etiology , Shock, Septic/complications , Shock, Septic/physiopathology , Adult , Cardiomyopathies/pathology , Edema/pathology , Female , Humans , Male , Middle Aged , Shock, Septic/pathology
3.
4.
Acta Cardiol ; 70(5): 501-9, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26567808

ABSTRACT

OBJECTIVE: A systematic review was carried out to study the pattern of BNP and NT-proBNP release after running. METHODS: Data were collected by searching the PubMed, ISI Web of Knowledge and Scopus databases. RESULTS: Fifty-three reports were identified as meeting the pre-specified criteria. Twenty-seven reports, representing 1,034 participants, presented data comparing post-running BNP or NT-proBNP levels with a pre-specified cut-off. Values exceeding the upper reference limit were seen in 22.9% and 35.9% of runners, respectively. CONCLUSION: Studies have shown post-running values exceeding the upper reference limit in up to a third of runners.


Subject(s)
Exercise/physiology , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Biomarkers/blood , Humans , Running , Time Factors , Up-Regulation
6.
Rev Port Cardiol ; 33(3): 175.e1-4, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24680554

ABSTRACT

Stress-induced cardiomyopathy, also known as 'broken heart syndrome' or Takotsubo cardiomyopathy, is characterized by transient systolic dysfunction of the apical and/or mid segments of the left ventricle, in the absence of significant coronary artery disease. We report the case of a 56-year-old male patient with chronic obstructive pulmonary disease (COPD), with stress-induced cardiomyopathy associated with the use of ipratropium bromide, administered in the context of an acute exacerbation of COPD.


Subject(s)
Bronchodilator Agents/adverse effects , Ipratropium/adverse effects , Takotsubo Cardiomyopathy/chemically induced , Bronchodilator Agents/therapeutic use , Humans , Ipratropium/therapeutic use , Male , Middle Aged , Pulmonary Disease, Chronic Obstructive/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...